GW Pharmaceuticals is the world leader in the development and commercialization of cannabinoid prescription medicines.

CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that Scott Giacobello, GW’s Chief Financial Officer and Stephen Schultz, GW’s Vice President of Investor Relations will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019 at 4:10 p.m. ET in New York, NY.